Ϫ1 ·day Ϫ1 ip for 5 consecutive days). We determined blood glucose, glucose tolerance, serum insulin, islet morphology, islet infiltration, serum cytokines, progenitor cell markers, immunomodulatory proteins, proliferation, apoptosis, and islet gene expression. IMT504 reduced glycemia, induced ␤-cell recovery, and impaired islet infiltration. IMT504 induced early blood glucose decrease and infiltration inhibition, increased ␤-cell proliferation and decreased apoptosis, increased islet indoleamine 2,3-dioxygenase (IDO) expression, and increased serum tumor necrosis factor and interleukin-6 (IL-6). IMT504 affected islet gene expression; preproinsulin-2, proglucagon, somatostatin, nestin, regenerating gene-1, and C-X-C motif ligand-1 cytokine (Cxcl1) increased in islets from diabetic mice and were decreased by IMT504. IMT504 downregulated platelet endothelial cell adhesion molecule-1 (Pecam1) in islets from control and diabetic mice, whereas it increased regenerating gene-2 (Reg2) in islets of diabetic mice. The IMT504-induced increase in IL-6 and islet IDO expression and decreased islet Pecam1 and Cxcl1 mRNA expression could participate in keeping leukocyte infiltration at bay, whereas upregulation of Reg2 may mediate ␤-cell regeneration. We conclude that IMT504 effectively reversed immunodependent diabetes in mice. Corroboration of these effects in a model of autoimmune diabetes more similar to human T1D could provide promising results for the treatment of this disease.
TYPE 1 DIABETES (T1D) is a progressive autoimmune destruction of ␤-cells. To prevent or cure T1D, research has aimed largely at understanding and modulating immunological responses (19, 43) and/or restoring ␤-cell mass, which is limited by the availability of transplantable ␤-cells and the need for chronic immunosuppression (1) . Furthermore, mesenchymal stem cells (MSCs) have been assayed as cell-based treatments for inflammatory disorders, including T1D (27) , since they promote immunomodulation and regeneration (47) . However, their translation into clinic has remained problematic (26) . An exciting alternative to MSC transplantation, but one related to it, consists in using therapeutic agents that can stimulate endogenous MSC expansion in the affected being.
Immunomodulatory oligonucleotides (ODNs) are synthetic molecules that activate immune cells. Two classes of ODNs have been identified, CpG ODNs (29) and non-CpG ODNs. Our group has identified a class of non-CpG ODNs called PyNTTTTGT, characterized for their active site (Py is C or T, and N is A, T, C, or G). IMT504, the prototype of this class, has two specific PyNTTTTGT sequences in its molecule (41) . CpG and PyNTTTTGT ODNs have a number of common characteristics but also remarkable differences (41) . Among the latter: 1) PyNTTTTGT ODNs do not induce IFN␣ secretion (13) , 2) they stimulate granulocyte-macrophage colonystimulating factor (GM-CSF) secretion in human CD56ϩ (NK/ NKT) cells (42) , and 3) they stimulate in vivo and in vitro MSCs proliferation (22) . Interestingly, IMT504 stimulated CD56ϩ NKT cells that have been postulated to convey peripheral tolerance and protection against autoimmune diabetes (30) . IMT504 also promoted marked improvement in rat models of bone injury (22) , neuropathic pain (7), and sepsis (5) . Regarding diabetes, streptozotocin-induced toxic diabetes in rats was reversed by IMT504, improving glycemia, increasing islet number, ␤-cell content, ␤-cell proliferation, and early expression of pancreatic progenitor markers (3) . Although IMT504 is active in rat and human cells, we have not yet demonstrated its effects in mice.
Since IMT504 has both immunomodulatory and regenerative properties, we investigated its actions in multiple low-dose streptozotocin-treated mice here, a model of immunodependent diabetes (48) that shares certain characteristics with human T1D.
MATERIALS AND METHODS

Oligonucleotides
HPLC purified ODNs with phosphorothioate internucleotide linkages were purchased from Oligos Etc. ODNs were suspended in depyrogenated water, assayed for lipopolysaccharide contamination, and kept at Ϫ20°C until they were used. Quality was verified as described (22) .
IMT504 is a 24-mer ODN (5=-TCATCATTTTGTCATTTTGT-CATT-3=). For the in vivo experiments, a control ODN consisting of 24-mer poly C ODN was used. For the in vitro experiments, CpG ODN 1826 (5=-TCCATGACGTTCCTGACGTT-3=), a specific mouse TLR9 agonist, was also tested.
Animals
Male 6-to 8-wk-old BALB/c mice from the IBYME colony were housed in groups in a temperature-controlled room, with lights on from 0700 to 1900 and free access to laboratory chow and tap water.
Experimental procedures were performed according to protocols approved by the Institutional Animal Care and Use Committee at Instituto de Biología y Medicina Experimental in accordance with the Division of Animal Welfare, Office for Protection from Research Risks, National Institutes of Health, Animal Welfare Assurance for the Institute of Biology and Experimental Medicine A#5072-01. All possible steps were taken to avoid animal suffering at each stage of the experiments.
Experimental Immunodependent Diabetes
Immunodependent diabetes was induced in mice by intraperitoneal (ip) injection of multiple low (subdiabetogenic) doses of streptozotocin (MLDS). Streptozotocin (STZ; Sigma-Aldrich, St. Louis, MO) was freshly diluted in 0.05 M sodium citrate buffer (pH 4.5), 40 mg/kg body wt, and injected daily for 5 consecutive days at noon. In this model, diabetes develops only when STZ induces both ␤-cell toxicity and T cell-dependent immune reactions (48) . Control animals were injected with citrate buffer. It took 15-20 days to observe consistent hyperglycemia. Only STZ-treated animals showing nonfasted blood glucose of Ն12 mM were considered diabetic. Glycemia in nonfasted control mice was 7.6 Ϯ 0.2 mM.
Preliminary Studies
Dose-response study. A dose-response effect of IMT504 on blood glucose in immunodependent diabetic mice was performed to determine the optimal dose in this species. MLDS mice (blood glucose Ն12 mM) and control mice were treated with IMT504 doses of 2, 10, or 20 mg·kg body wt Ϫ1 ·day Ϫ1 . Animals were randomly assigned to the treatment groups and injected subcutaneously (sc) for 10 consecutive days (days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . The groups were as follows: control-IMT504 (2), control-IMT504 (10), control-IMT504 (20) , STZ-IMT504 (2), STZ-IMT504 (10) , and STZ-IMT504 (20) . Control diabetic and nondiabetic animals received saline (STZ-Saline, control-saline). Nonfasted glycemia was determined on day 1 before treatment initiation and on day 11 (1 day after the last IMT504 injection). Percentages of animals responding to treatment were calculated (n ϭ 5-7).
In vitro bone marrow fibroblast colony-forming units. To assess whether IMT504 was able to stimulate the cloning efficiency of MSCs [fibroblast colony-forming unit (CFU-F) assay], mice were anesthetized with ketamine-xylazine (50/5 mg/kg) and euthanized for bone marrow (BM) harvesting. Procedures were performed as described previously (22) . Briefly, after epiphyses were removed and access to the marrow cavities was gained, whole BM plugs were flushed out from femoral bones using a 1-ml syringe with ␣-medium (␣-MEM; Gibco) supplemented with 100 IU/ml gentamicin, 25 IU/ml heparin (Larjan, Buenos Aires, Argentina), and 2.5 g/ml amphotericin B (PAA Laboratories, Pasching, Austria). The cell suspension was centrifuged at 400 g for 10 min, and the pellet was suspended in fresh medium. This procedure was repeated twice. Cell concentration was evaluated by microscopic cell counting using a Neubauer hemocytometer in samples treated with 3% acetic acid. Cell viability was determined using the trypan blue staining method.
The cloning efficiency of BM-MSC was evaluated by CFU-F assay (1 MSC ϭ 1 CFU-F). BM cells (3 ϫ 10 6 /well) were seeded in 25-cm 2 tissue culture flasks (Orange Scientific) containing ␣-medium supplemented with 100 IU/ml gentamicin (Gibco), 2.5 g/ml amphotericin B (Gibco), 2 mM L-glutamine (Sigma-Aldrich), and 10% FCS (Gibco) and incubated at 37°C under a 5% CO 2 atmosphere, as described previously. Cultures were treated with a single dose of 4 g/ml IMT504, 4 g/ml CpG ODN 1826, or PBS (control) and incubated for 7 days. After a 7-day culture, nonadherent cells were removed by washing twice with PBS. Thereafter, fresh medium was added, and incubation proceeded for 7 more days under the same conditions. On day 14, cells were washed twice with PBS, fixed with 100% methanol for 15 min, and stained using Giemsa solution (Merck). Cells and colonies were observed and counted using an optical microscope. A CFU-F was defined as a group of at least 50 cells with an approximately circular disposition. The number of colonies counted in each culture treated with PBS (controls) was considered 100%. The percent variation with regard to controls in each experiment was calculated for each stimulus (n ϭ 12).
First Experimental Design: Long-Term Effects of IMT504 in Diabetic Mice
MLDS mice (blood glucose Ն12 mM) and control mice were injected sc with IMT504 (20mg/kg BW) or saline, respectively, for 10 consecutive days (days 1-10) and then for 5 consecutive days starting on days 21 and 36 (total no. of doses : 20) . Glycemia was measured in tail blood samples in nonfasted conditions on days 1, 6, 11, 17, 21, 26, 29, 32, 36, 41, 46, 53 , and 66 at 11-12 AM (last IMT504 injection on day 40). Intraperitoneal glucose tolerance tests (IPGTT) were performed on day 60. On day 67, mice were anesthetized with 2% wt/vol avertin (12 ml/kg ip; Sigma-Aldrich), an intracardiac blood sample was obtained for serum cytokine determinations, and mice were then euthanized by transcardiac perfusion with 0.9% saline followed by 4% paraformaldehyde in PBS, pH 7.4. Pancreases were excised and processed for immunohistochemistry (n ϭ 6 -8) (3).
Blood Glucose
Blood glucose was monitored in tail blood samples using a One touch Ultra glucose meter (LifeScan, New Brunswick, NJ); strips were kindly donated by Johnson & Johnson.
IPGTT
IPGTTs were performed on day 60 in mice from the first experimental design. Overnight-fasted animals were injected ip with 2 g/kg BW glucose, and glycemia was evaluated at 0, 30, 60, 90, and 120 min post-glucose administration (3).
Serum Insulin
Insulin was determined using an ultrasensitive mouse insulin ELISA kit (Crystal Chem, Chicago, IL) in serum samples obtained from tail blood at time 0 during the IPGTT on day 60, as described (3).
HOMA-IR and HOMA-␤-Cell
HOMA-IR and HOMA-␤-cell indexes were calculated using the overnight-fasted blood glucose and serum insulin levels in the first experimental design and the 3-h-fasted blood glucose and serum insulin levels in the second experimental design:
HOMA-IR ϭ fasting insulin ͑U ⁄ ml͒ ϫ fasting glucose ͑mmol ⁄ l͒ ⁄ 22.5 HOMA-␤-cell ϭ 20 ϫ fasting insulin ͑U ⁄ ml͒ ⁄ ͓fasting glucose ͑mmol ⁄ l͒ Ϫ 3.5͔.
Leukocyte Infiltration
Five-micrometer pancreas sections from all animals (n ϭ 4 -6) were stained with hematoxylin-eosin and analyzed by light microscopy. Insulitis scoring was evaluated according to the following criteria: no insulitis (score 0); peri-insulitis, insulitis restricted to the periphery of islets (score 1); moderate insulitis, Ͻ50% of the islet infiltrated (score 2); and severe insulitis, Ն50% of the islet area infiltrated (score 3), as described (14) . Digital images were taken at ϫ40 magnifications using a Nikon Photomicroscope Eclipse 200. The microscope operator was blinded for the treatments when scoring for insulitis. Insulitis index was calculated as described (31)
where n0, n1, n2, and n3 are the number of islets scored in grades 0, 1, 2 and 3 respectively.
Cytokine Profile
A set of seven cytokines related to Th1 (IFN␥, IL-2, and TNF), Th2 (IL-4, IL-6, and IL-10), and Th17 (IL-17A) immune responses was measured using the Becton Dickinson Th1-Th2-Th17 CBA kit [BD Cytometric Bead Array (CBA) Mouse Th1/Th2/Th17 Cytokine Kit, catalog no. 560485; BD Biosciences, San Jose, CA] in serum samples obtained at euthanization in both experimental designs (n ϭ 4 -8).
Endocrine Pancreas Histological and Morphometric Analysis
Double staining for glucagon and insulin. Four sections (5 m) from different regions of the pancreas from each animal were used for double staining with anti-insulin and anti-glucagon antibodies in both the long-term (n ϭ 4 -6/group) and short-term experimental designs (n ϭ 4 -6/group). Slides were first overnight (ON) incubated with rabbit anti-glucagon antibody (SC 13091, 1:300; Santa Cruz Biotechnology, Santa Cruz, CA), followed by secondary antibody (biotinylated goat anti-rabbit IgG, BA-1000, 1:200; Vector Laboratories, Burlingame, CA) and Vectastain ABC kit (PK-6100; Vector Laboratories) and 3,3=-diaminobenzidine (DAB; Roche, Mannheim, Germany). Insulin was detected with guinea pig anti-insulin antibody (ON incubation, I8510, 1:300; Sigma-Aldrich), followed by a secondary antibody (biotinylated goat anti-guinea pig IgG, Vector BA-7000, 1:200) and alkaline phospha- 
Cxcl1, C motif ligand-1 cytokine; Gcg, proglucagon; Ins1 and -2, preproinsulin 1 and 2, respectively; Mafa, v-Maf musculoaponeurotic fibrosarcoma oncogene family, protein A; Nes, nestin (neuroectodermal stem cell marker); Pdx1, pancreatic and duodenal homeobox 1; Pecam1, platelet endothelial cell adhesion molecule-1; Ppib, cyclophilin B; Ppy, pancreatic polypeptide; Reg1 and -2, regenerating genes 1 and 2, Sst, somatostatin. A: IMT504 dose-response study: 2, 10, or 20 mg/kg IMT504 were injected subcutaneously (sc) daily to MLDS (glycemia Ն12 mM) and control mice for 10 days. Glycemia was measured on day 1, before IMT504 treatment started, and on day 11, 1 day after the last IMT504 dose. Both 10 and 20 mg/kg IMT504 significantly lowered blood glucose, repeated-measures 2-way ANOVA. Factors: treatment days; interaction: P Ͻ 0.001. a Different from controls on day 1, P Ͻ 0.02; b different from controls on day 11, P Ͻ 0.001; *different from day 1 in the same group, P Ͻ 0.01. Inset: %animals responding to treatment; none of the 2 mg/kg IMT504-injected MLDS mice responded to treatment (0 of 7 ϭ 0%), whereas both 10 (4 of 6 ϭ 67%) and 20 mg/kg (6 of 7 ϭ 86%) showed a satisfactory response to treatment, without significant differences between them. tase Vectastain ABC-AP kit (Vector AK-5000) combined with Vector red substrate (Vector SK-5100). Negative controls were used for assaying nonspecific staining. Sections were mounted on aqueous medium without counterstain. Digital images were taken at ϫ10 and ϫ40 magnifications using a Nikon Photomicroscope Eclipse 200. Image analysis was performed with NIS-Elements BR 2.30 software.
Total pancreas area for each section was determined in microphotographs covering all the pancreas sections. Islet number and total islet area, both of which are relative to square millimeters of total pancreas area, were calculated. Glucagon-positive and insulin-positive areas per islet area were also calculated. Data from sections of the same slide were averaged.
Second Experimental Design: Short-Term Effects of IMT504 in Diabetic Mice
With the aim of establishing the early mechanisms by which IMT504 elicits reversion of the diabetic state, MLDS mice (blood glucose Ն12 mM) and control mice were treated daily with IMT504 or poly C ODN (a control for specificity, 20 mg/kg body wt sc), and blood glucose was monitored every day. STZ-IMT504 mice were euthanized after two consecutive decreases in blood glucose in each animal. The number of IMT504 injections per animal to obtain this result in glycemia varied between two and six. Groups of controlsaline, control-IMT504, STZ-poly C, and STZ-saline animals were euthanized at the same time as STZ-IMT504 animals. After the nonfasted blood glucose levels were determined, mice were fasted for 3 h, blood glucose was measured, they were then anesthetized with avertin (as above), a transcardiac blood sample was obtained (for serum insulin and cytokines determinations), and they were then euthanized by transcardiac perfusion with 0.9% saline followed by 4% paraformaldehyde in PBS, pH 7.4. Pancreases were excised and processed for immunohistochemical analysis (n ϭ 4 -6).
Blood glucose, serum insulin, HOMA-IR and HOMA-␤-cell, leukocyte infiltration, and cytokine profile were performed as stated above.
Pancreas Histological and Morphometric Analysis
Double staining for glucagon and insulin was performed as described above.
Double staining for PCNA and insulin. Two sections (5 m) from different regions of each pancreas were used for the double staining with insulin and proliferating cell nuclear antigen (PCNA) in animals from the short-term experimental design (n ϭ 4 -6/group). For PCNA, tissues were blocked for 1 h with PBS-2% BSA supplemented with 5% goat serum and later incubated ON with rabbit anti-PCNA antibody (1:200 in PBS-2% BSA, sc-7907; Santa Cruz Biotechnology, Dallas, TX) at 4°C. Incubation with 1:200 secondary antibody (goat biotinylated anti-rabbit IgG, BA-1000; Vector Laboratories) lasted for 1 h at room temperature. Slides were then incubated with the Vectastain ABC-AP Kit (AK-5000; Vector Laboratories), and the Vector Blue substrate kit (SK-5300; Vector Laboratories) was then used for staining. Insulin staining was performed as above.
The number of PCNA positive ␤-cells and PCNA positive non-␤-cells/islet were calculated.
Apoptosis evaluation. The apoptotic cells were evaluated using a DeadEnd Fluorometric TUNEL System commercial kit (G3250; Promega) according to the manufacturer's protocol (green staining) in sections of pancreases of the short-term experimental design. We used 1 g/ml DAPI for 5 min at room temperature in the dark as a nuclear stain (blue staining) and rabbit anti-glucagon antibody (1:300) followed by anti-rabbit IgG (H ϩ L)-Texas Red (red staining; Vector Laboratories) to identify ␣-cells. Immediately, the samples were analyzed under a confocal microscope to view the green and red fluorescence at 520 Ϯ 20 nm and Ͼ620 nm, respectively. The number of apoptotic islets/total islets and the number of apoptotic nuclei per islet were calculated (n ϭ 4 -6).
Triple immunostaining for Pdx1 or Nkx6.1 together with insulin and glucagon. Insulin was determined as described above. Glucagon were detected as above but followed by the Vectastain ABC-AP Kit combined with the Vector blue AP Kit. The number of Pdx1ϩ or Nkx6.1ϩ ␣-and ␤-cells per positive islets were calculated (n ϭ 4 -6).
Immunostaining for indoleamine 2,3-dioxygenase and TSG-6. Pancreas sections were incubated with rabbit anti-indoleamine 2,3-dioxygenase (IDO; sc-25809, 1:100, ON at 4°C; Santa Cruz Biotechnology) or rabbit anti-TSG-6 (sc-30140, 1:100, ON at 4°C; Santa Cruz Biotechnology) antibodies and the corresponding second antibody (goat biotinylated anti-rabbit IgG, 1:200, BA-1000 Vector Labs), which was revealed with DAB, and then counterstained with hematoxylin. IDO-or TSG-6-positive islets per total islets were calculated (n ϭ 4 -6).
Islet Isolation, RNA Extraction, and Gene Expression Assays
Pancreatic islets were isolated from mice of the second experimental design, as described previously with minor modifications (4). , different from control-saline, P Ͻ 0.01. B: fasted glycemia was determined on day 60 during the intraperitoneal glucose tolerance test (IPGTT). IMT504 decreased blood glucose to control levels; ANOVA, P Ͻ 0.001. #Different from all, P Ͻ 0.05. C: fasted serum insulin was determined on day 60 during the IPGTT. No differences were observed among groups; ANOVA, NS. D: HOMA-␤-cell was calculated with fasted blood glucose and fasted serum insulin determined on day 60. IMT504 normalized this parameter; ANOVA, P Ͻ 0.05. *Different from all, P Ͻ 0.05. E: homeostasis model assessment of insulin resistance (HOMA-IR) was calculated with fasted blood glucose and fasted serum insulin determined on day 60. IMT504 partially reverted this parameter, as it was not significantly different from either controls or STZ-saline; ANOVA, P Ͻ 0.01; *Different from control-saline and control-IMT504, P Ͻ 0.05. F: IPGTT; glucose (2 g/kg ip) excursion curves were evaluated for all groups. IMT504 partially improved this parameter, as it was able to control glucose overload up to 30 min; repeated-measures 2-way ANOVA. Factors: treatment/time; interaction: P Ͻ 0.001.
a Different from all, P Ͻ 0.05; b different from controls, P Ͻ 0.05; c different from controls, P Ͻ 0.01. G: area under the curve (AUC) IPGTT; the area under the glucose curve was calculated. IMT504 decreased this parameter significantly in diabetic mice with respect to STZ-saline, albeit not attaining control levels; ANOVA, P Ͻ 0.001. *STZ-saline, different from all, P Ͻ 0.04; #STZ-IMT504, different from all, P Ͻ 0.04. Representative images of insulin (red) and glucagon (brown) double-stained islets; magnification, ϫ400. H: islet no./mm 2 pancreas was calculated for all groups. STZ-saline induced a decreased in islet number that was reversed by IMT504; ANOVA, P Ͻ 0.01. *Different from all, P Ͻ 0.01. I: islet area/mm 2 pancreas was calculated for all groups. STZ-saline induced a decrease in islet area with regard to control that was partially reversed by IMT504; ANOVA, P Ͻ 0.01. *Different from control-saline and control-IMT504, P Ͻ 0.05. J: glucagon-positive (black bars) and insulin-positive (open bars) areas/islet area were calculated for all groups. Glucagon area did not vary among groups; ANOVA, NS. Insulin area was decreased in STZ-saline islets and partially recovered by IMT504 treatment; ANOVA, P Ͻ 0.001. *Different from all, P Ͻ 0.05. Briefly, we injected 3 ml of a liberase solution into the pancreatic duct in anesthetized mice (Liberase TL Research Grade, 05401020001, Roche; commercialized by Sigma-Aldrich, which was dissolved in RPMI medium; RPMI, 31800022; Gibco, Carlsbad, CA). The liberase concentration was 0.155 mg/ml. The pancreas was then gently removed for its further digestion in liberase solution at 37°C for 14 min in a 50-ml Falcon tube. The digestion was stopped by 40 ml of ice-cold RPMI 1640 supplemented with 10% FBS. Islets were handpicked under a dissecting microscope into fresh RPMI-10% FBS and then hand-picked for a second time into TRIzol reagent (Invitrogen, Carlsbad, CA) and homogenized for further RNA extraction.
Total RNA was isolated from TRIzol homogenates according to the manufacturer's protocol and kept at Ϫ70°C until being purified further with a NucleoSpin RNA kit (Macherey-Nagel, Bethlehem, PA); 0.5 g For quantitative real-time PCR, primer sets were chosen for the specific amplification of the following murine genes: preproinsulin 1 (Ins1), preproinsulin 2 (Ins2), proglucagon (Gcg), pancreatic polypeptide (Ppy), somatostatin (Sst), pancreatic and duodenal homeobox 1 (Pdx1), v-Maf musculoaponeurotic fibrosarcoma oncogene family, protein A (MafA), platelet endothelial cell adhesion molecule (Pecam1; also known as cluster of differentiation 31), regenerating genes 1 and 2 (Reg1 and Reg2), nestin (neuroectodermal stem cell marker) (Nes), C-X-C motif ligand 1 cytokine (Cxcl1), and cyclophilin B (Ppib) as the housekeeping control gene (Table 1) .
Target cDNA quantification was performed by kinetic PCR in a total volume of 10 l using 5 ϫ HOT FIREPol EvaGreen qPCR Mix Plus (Solis BioDyne, Tartu, Estonia) according to the manufacturer's protocol, with an additional annealing step. Amplification was carried out in an ABI 7500 sequence detection system (Applied Biosystems, Carlsbad, CA). Results were validated based on the quality of the dissociation curves, and the product purity was confirmed by 2.3% agarose gel electrophoresis. Each sample was analyzed in duplicate along with nontemplate controls to monitor nucleic acid contamination.
Quantitative differences in the cDNA target between samples were determined using the mathematical model of Pfaffl, as described previously (n ϭ 5-6) (9).
Statistical Analysis
Results are expressed as means Ϯ SE. Differences between means were analyzed by one-way ANOVA, followed by post hoc tests; for multiple determinations in the same animal, we used two-way ANOVA with repeated-measures design (Statistica Release 7). Differences in percentages between two groups were analyzed with the 2 test; when more than two groups were compared, the data were arcsine transformed and analyzed by ANOVA. In all cases, P Ͻ 0.05 was considered significant.
RESULTS
Preliminary Studies
Preliminary tests were performed to confirm the biological effect and determine the optimal dose of IMT504 in MLDS mice. Moreover, its effect on in vitro mouse MSC proliferation was also analyzed.
Dose-Response Study
Both 10 and 20 mg/kg IMT504 lowered blood glucose in MLDS mice significantly, whereas 2 mg/kg was ineffective (repeated-measures 2-way ANOVA, interaction P Ͻ 0.001, STZ-IMT504 10 mg/kg: day 11 vs. day 1, P Ͻ 0.01; STZ-IMT504 20 mg/kg: day 11 vs. day 1, P Ͻ 0.01; Fig. 1A ). The percentage of animals responding to treatment increased with 20 (6 of 7) vs. 10 mg/kg (4 of 6), albeit not significantly (NS; 86 vs. 67%, 2 ; Fig. 1A, inset) , whereas none of the 2 mg/kg injected animals responded to treatment (0/7). We selected 20 mg/kg as the optimal dose for treatment in mice.
In Vitro Mouse BM-MSC CFU-F Formation
IMT504 increased the number of CFU-Fs of mouse BM cells significantly compared with controls (ANOVA: P Ͻ 0.05, 
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Fig . 3 . First experimental design. Immune parameters. Representative photomicrographs of hematoxylin-stained sections; magnification, ϫ400. A: insulitis scores in Langerhans islets. Insulitis scoring was evaluated according to the following criteria: no insulitis (score 0); peri-insulitis, insulitis restricted to the periphery of islets (score 1); moderate insulitis, Ͻ50% of the islet infiltrated (score 2); and severe insulitis, Ն50% or higher of the islet area infiltrated (score 3). %Islets in each category was calculated for all of the experimental groups. B: insulitis index was calculated as follows:
, where n0, n1, n2, and n3 are the nos. of islets scored in grades 0, 1, 2, and 3, respectively. IMT504 reduced the insulitis index significantly in STZ-IMT504 mice; ANOVA, P Ͻ 0.001. *Different from all, P Ͻ 0.001. Fig. 1B ). In contrast, CpG ODN 1826, a specific mouse TLR9 agonist, had no effect.
First Experimental Design: Long-Term Effect of IMT504 in MLDS Mice
Once the optimal dose was determined, the long-term effect of IMT504 was confirmed by a set of parameters that included functional pancreatic tests, islet morphology, and leukocyte infiltration.
Glucose metabolism and islet morphology. Blood glucose levels were similar in all mice at the time of them being assigned to the diabetic (MLDS) or control (vehicle-injected) groups (nonfasted blood glucose: control-saline ϭ 8.3 Ϯ 0.7, control-IMT504 ϭ 8.0 Ϯ 0.6, STZ-saline ϭ 8.0 Ϯ 0.4, STZ-IMT504 ϭ 7.6 Ϯ 0.6, ANOVA; NS).
After 15-20 days of MLDS treatment, mice developed hyperglycemia ( Fig. 2A) , and IMT504 treatment, or saline as control, was commenced (day 1). Blood glucose increased progressively in STZ-saline mice during 10 wk of evaluation, whereas it decreased significantly in STZ-IMT504 mice (repeated-measures 2-way ANOVA, interaction P Ͻ 0.001, STZ-IMT504 different from STZ-saline on days 6, 11, 21, 26, 29, 32, 36, 41, 46, 53 , and 66, P Ͻ 0.01 or less; Fig. 2A ). Eighty-eight percent of STZ-IMT504 animals responded to treatment (7 of 8), whereas 20% of STZ-saline mice (2 of 10) showed spontaneous diabetes reversion ( 2 : P Ͻ 0.025). The graphs in Fig. 2 , B-J, show data of STZ-IMT504 responding animals. The first five IMT504 doses sufficed to normalize glycemia. However, after drug interruption, a gradual increase in blood glucose occurred that was normalized upon reinitiating IMT504 treatment. At the end of the experiment (day 66), 26 days after the last IMT504 dose, blood glucose was significantly lower in STZ-IMT504 than in diabetic mice, albeit higher than in controls (repeated-measures 2-way ANOVA, interaction P Ͻ 0.001; day 66: STZ-IMT504 vs. control-saline, control-IMT504, and STZ-saline, P Ͻ 0.01).
Body weight was determined in these mice on the 1st day of each treatment, when the first dose of STZ was administered and when the first dose of each IMT504 cycle was administered (days 1, 21, and 36) and also on the day of euthanization (day 66). We did not observe any significant differences in body weight due to IMT504 treatment in either controls or MLDS-treated mice (not shown).
IPGTT was performed 20 days after the last IMT504 dose. Fasted blood glucose in STZ-IMT504 mice was similar to controls and significantly lower than in STZ-saline (ANOVA, P Ͻ 0.001; STZ-IMT504 vs. STZ-saline, P Ͻ 0.05; Fig. 2B ). Fasted serum insulin was similar among groups (ANOVA: NS) (Fig. 2C) . HOMA indexes derive from relationships between fasted blood glucose and serum insulin levels and are used here as an approximation to insulin secretion and action. IMT504 normalized ␤-cell function (ANOVA, P Ͻ 0.05, STZ-saline vs. control-saline, control-IMT504, and STZ-IMT504, P Ͻ 0.05, HOMA-␤-cell; Fig. 2D ) and improved insulin resistance (ANOVA, P Ͻ 0.01, STZ-saline vs. control-saline and control-IMT504, P Ͻ 0.05, HOMA-IR; Fig. 2E ). The glucose excursion was severely impaired in STZ-saline mice (Fig. 2F ) and improved by IMT504, which also significantly decreased the area under the glucose curve (ANOVA, P Ͻ 0.001, STZ-IMT504 vs. control-saline, control-IMT504, and STZ-saline, P Ͻ 0.04; Fig. 2G ).
Islet number/pancreas area (Fig. 2H ) and islet area/pancreas area (Fig. 2I ) in STZ-IMT504 mice did not differ from controls, demonstrating at least partial recovery, whereas both decreased significantly in diabetics (islet number/pancreas area: ANOVA, P Ͻ 0.01, STZ-saline vs. control-saline, control-IMT504, and STZ-IMT504, P Ͻ 0.01; islet area/pancreas area: ANOVA P Ͻ 0.01, STZ-saline vs. control-saline and control-IMT504, P Ͻ 0.05). Additionally, STZ induced a significant decrease in ␤-cell area (Fig. 2J ) that reversed significantly with IMT504, albeit not attaining control levels (ANOVA, P Ͻ 0.001, STZ-IMT504 vs. control-saline, control-IMT504, and STZ-saline, P Ͻ 0.05).
Immune parameters. MLDS mice showed marked insulitis (Fig. 3A) ; this was significantly reversed by IMT504 (Fig. 3B) , demonstrating effective inhibition of leukocyte infiltration even after 26 days without treatment (insulitis index: ANOVA, P Ͻ 0.001, STZ-saline vs. control-saline, control-IMT504, and STZ-IMT504, P Ͻ 0.001). Circulating cytokines did not differ among groups (not shown).
Second Experimental Design: Short-Term Effect of IMT504 in MLDS Mice
Taking into account that IMT540 showed significant, longlasting improvement in immunodependent diabetes, we studied its effect shortly after treatment initiation when the regenerative process was commencing.
Glucose metabolism and islet morphology. MLDS mice were treated daily with 20 mg/kg IMT504 and euthanized after two consecutive drops in blood glucose. A group of MLDS mice was treated similarly with a poly C ODN, with the same Fig. 4 . Second experimental design. Glucose metabolism and islet morphology. A: nonfasted glycemia evolution; MLDS mice (blood glucose Ն12 mM) and control mice were treated daily with 20 mg/kg IMT504 or poly C oligonucleotides (ODN; a control for specificity, 20 mg/kg body wt sc), and blood glucose was monitored every day. STZ-IMT504 mice were euthanized after 2 consecutive decreases in blood glucose in each animal. The no. of IMT504 injections/animal to obtain this result in glycemia varied between 2 and 6. B: nonfasted glycemia before treatment initiation and at euthanization in each animal. IMT504 significantly lowered blood glucose to control levels, whereas poly C ODN had no effect; repeated-measures 2-way ANOVA, interaction P Ͻ 0.001. Different letters indicate significant differences, P Ͻ 0.001. C: fasted glycemia at euthanization. IMT504 significantly normalized fasted blood glucose in STZ-IMT504 mice, whereas poly C ODN had no effect; ANOVA, P Ͻ 0.001. *Different from all, P Ͻ 0.001. D: fasted serum insulin at euthanization did not differ among groups; ANOVA, NS. E: HOMA-␤-cell. IMT504 normalized this parameter in STZ-IMT504 mice; ANOVA, P Ͻ 0.001. *Different from control-saline, control-IMT504, and STZ-IMT504, P Ͻ 0.01; #different from control-saline, STZ-saline, and STZ-Poly C, P Ͻ 0.04. F: HOMA-IR. This parameter was normalized in STZ-IMT504 mice; ANOVA, P Ͻ 0.001. *Different from controls and STZ-IMT504, P Ͻ 0.001. Representative images of insulin (red) and glucagon (brown) double-stained islets. G: islet no./mm 2 pancreas. Islet no./mm 2 tended to decrease in STZ-saline mice and was restored by IMT504 in diabetic mice; ANOVA, P Ͻ 0.01. *Different from control-IMT504 and STZ-IMT504, P Ͻ 0.03. H: islet area/mm 2 pancreas. Islet area/mm 2 tended to decrease in STZ-saline mice and was restored by IMT504 in diabetic mice ANOVA, P Ͻ 0.05. *Different from control-IMT504 and STZ-IMT504, P Ͻ 0.02. I: insulin-glucagon area/islet area (%); insulin area decreased in both STZ-saline and STZ-IMT504 islets; ANOVA, P Ͻ 0.001. phosphorothioate backbone and length (20 mg/kg), to test the specificity of the IMT504 response. Nonfasted saline-treated diabetic mice were hyperglycemic; in contrast, two to six doses of IMT504 significantly lowered glycemia to control levels (Fig. 4, A and B) , whereas poly C ODN was ineffective (repeated-measures 2-way ANOVA, interaction P Ͻ 0.001, STZ-IMT504, blood glucose at euthanization vs. on day 1, P Ͻ 0.001). 
ControlSaline
Control-IMT504 After 3 h of fasting, blood glucose showed the same pattern as in nonfasted mice (ANOVA: P Ͻ 0.001, STZ-saline and STZ-poly C vs. control-saline, control-IMT504, and STZ-IMT504, P Ͻ 0.001; Fig. 4C ). Fasted insulin did not vary among groups (ANOVA: NS; Fig. 4D ). HOMA-␤-cell (Fig.  4E ) and HOMA-IR (Fig. 4F) were normalized by IMT504 but not by poly C ODN (HOMA-␤-cell, ANOVA: P Ͻ 0.001, STZ-saline and STZ-poly C vs. control-saline, control-IMT504, and STZ-IMT504, P Ͻ 0.01; HOMA-IR, ANOVA: P Ͻ 0.001, STZ-saline, and STZ-poly C vs. control-saline, control-IMT504, and STZ-IMT504, P Ͻ 0.001).
STZSaline
STZ-IMT504
Islet number/pancreas area (Fig. 4G ) and islet area/pancreas area (Fig. 4H ) decreased in STZ-saline and were normalized by IMT504 (islet number/pancreas area, ANOVA: P Ͻ 0.01, STZ-saline vs. control-IMT504 and STZ-IMT504, P Ͻ 0.03; islet area/pancreas area, ANOVA: P Ͻ 0.05, STZ-saline vs. control-IMT504 and STZ-IMT504, P Ͻ 0.02). ␤-Cell area/islet area decreased in STZ-saline and STZ-IMT504 (ANOVA: P Ͻ 0.001, STZ-saline and STZ-IMT504 vs. control-saline and control-IMT504, P Ͻ 0.01), whereas ␣-cell area/islet area increased in STZ-saline and reversed with IMT504 (ANOVA, P Ͻ 0.001, STZ-saline vs. control-saline, control-IMT504, and STZ-IMT504, P Ͻ 0.01; Fig. 4I) .
Proliferation, apoptosis, and progenitor cell markers. STZ induced a near-significant (P Ͻ 0.07) decrease in ␤-cell proliferation. Conversely, PCNAϩ nuclei/islet increased significantly in STZ-IMT504 mice in both ␤-and non-␤ (presumably ␣)-cells [no. of PCNAϩ ␤-cells/islet, ANOVA: P Ͻ 0.02, STZ-IMT504 vs. STZ-saline, P Ͻ 0.05 (Fig. 5A) ; no. of PCNAϩ non-␤-cells/islet, ANOVA: P Ͻ 0.05, STZ-IMT504 vs. control-saline and control-IMT504, P Ͻ 0.03 (Fig. 5B)] .
STZ increased apoptosis in islets, likely in ␤-cells, as ␣-cells (stained red) did not show apoptosis. IMT504 partially reversed this effect [no. of apoptotic islets/total islets, ANOVA: P Ͻ 0.01, control-saline vs. STZ-saline, P Ͻ 0.05 (Fig. 5C) ; no. of apoptotic nuclei/positive islets, ANOVA: P Ͻ 0.05, control-saline and control-IMT504 vs. STZ-saline, P Ͻ 0.05 (Fig. 5D)] .
The total number of Pdx1ϩ and Nkx6.1ϩ nuclei/islets did not vary among groups (not shown). Interestingly, the number of Pdx1ϩ or Nkx6.1ϩ ␤-cells did not vary due to treatment (ANOVA: NS) (Fig. 5, E and G) ; instead, the diabetic state (STZ-saline and STZ-IMT504) induced a significant increase in Pdx1 and Nkx6.1 expression in ␣-cells that usually do not express these markers in adulthood [Pdx1, ANOVA: P Ͻ 0.01, STZ-saline and STZ-IMT504 vs. control-saline and control-IMT504, P Ͻ 0.01 (Fig. 5F) ; Nkx6.1, ANOVA: P Ͻ 0.05, STZ-saline and STZ-IMT504 vs. control-saline and control-IMT504, P Ͻ 0.05 (Fig. 5H)] .
Immune parameters. MLDS triggered islet leukocyte infiltration. IMT504 significantly reduced infiltration to near-normal levels (Fig. 6A) . Insulitis index was increased in STZsaline islets and reversed significantly by IMT504 (Fig. 6B ) (ANOVA: P Ͻ 0.001, STZ-saline vs. control-saline, control-IMT504 and STZ-IMT504, P Ͻ 0.01).
IMT504 induced specific increases in IL-6 and TNF in the control-IMT504 and STZ-IMT504 groups, suggesting IMT504-dependent effects (IL-6, ANOVA: P Ͻ 0.01, control-IMT504 and STZ-IMT504 vs. control-saline and STZsaline, P Ͻ 0.04; TNF, ANOVA: P Ͻ 0.001, control-IMT504 and STZ-IMT504 vs. control-saline and STZ-saline, P Ͻ 0.05; Fig. 6C ); no differences were observed for the other cytokines.
IDO and TSG-6 have anti-inflammatory effects (28, 35) . IMT504 induced an increase in IDO expression in diabetic islets, suggesting that this may be one mechanism by which it controls islet infiltration (ANOVA: P Ͻ 0.01, STZ-IMT504 vs. control-saline and control-IMT504, P Ͻ 0.03; Fig. 6D ). Because we detected an increase in TNF in IMT504-treated animals and this cytokine stimulates tumor necrosis factorinducible gene 6 protein (TSG-6) production, we evaluated its expression, finding no differences due to treatment (not shown).
Islet gene expression. In isolated islets, we evaluated expression of genes encoding for islet hormones, transcription factors, and other proteins that could play a role in ␤-cell survival, apoptosis, and/or regeneration.
In MLDS islets, we observed increased expression of Ins2, Gcg, and Sst (Fig. 7, A-C) ; IMT504 partially or totally reversed these increases (Ins2/Ppib, ANOVA: P Ͻ 0.001, STZsaline vs. control-saline, control-IMT504 and STZ-IMT504, P Ͻ 0.04; Gcg/Ppib, ANOVA: P Ͻ 0.001, STZ-saline vs. control-saline, control-IMT504, and STZ-IMT504, P Ͻ 0.002; Sst/Ppib, ANOVA: P Ͻ 0.02, STZ-saline vs. control-saline, control-IMT504, and STZ-IMT504, P Ͻ 0.03).
Ins1 and Ppy were unaltered (ANOVA, NS; Fig. 7 , D and E), whereas Pdx1 and Mafa decreased in both STZ-saline and STZ-IMT504 islets, but only Mafa attained statistical significance (Fig. 6 , F and G) (ANOVA: P Ͻ 0.04, control-saline vs. STZ-saline and STZ-IMT504, P Ͻ 0.03).
Nestin, Reg1, and Cxcl1 increased in STZ-saline islets and were reversed by IMT504 (Nes/Ppib, ANOVA: P Ͻ 0.01, STZ-saline vs. control-saline, control-IMT504, and STZ-IMT504, P Ͻ 0.03; Reg1/Ppib, ANOVA: P Ͻ 0.02, STZ- Fig. 5 . Second experimental design. Proliferation, apoptosis, and progenitor cell markers. Left: representative photomicrographs of islets. A and B: insulin (red) and proliferating cell nuclear antigen (PCNA; blue). Proliferation of islet cells was evaluated by PCNA staining. A: no. of PCNAϩ ␤-cells/islet tended to decrease in STZ-saline islets with regard to controls and increase in STZ-IMT504 islets; ANOVA, P Ͻ 0.02. *Different from STZ-IMT504, P Ͻ 0.05. B: no. of PCNAϩ non-␤-cell/islet (presumably ␣-cells) increased in STZ-IMT504 islets; ANOVA, P Ͻ 0.05. *STZ-IMT504, different from control-saline and control-IMT504, P Ͻ 0.03. C and D: glucagon (red), apoptotic nuclei (green), and other nuclei (blue). Apoptosis in islet cells was evaluated by the TUNEL method. C: no. of apoptotic islets/total islets increased in STZ-saline and was partially reversed by IMT504; ANOVA, P Ͻ 0.01. *Different from STZ-saline, P Ͻ 0.05. D: no. of apoptotic nuclei/positive islet (presumably in ␤-cells, as ␣-cells did not show apoptosis) increased in STZ-saline islets and was normalized by IMT504; ANOVA, P Ͻ 0.05. *Different from STZ-saline, P Ͻ 0.05. E and F: insulin (red), glucagon (blue), and Pdx-1 (brown). Expression of pancreatic and duodenal homeobox 1 (Pdx-1), a characteristic marker of adult ␤-cells, was evaluated in islets from all experimental groups. E: no. of Pdx-1ϩ ␤-cells/islet did not vary among groups; ANOVA, NS. F: no. of Pdx-1ϩ ␣-cells/islet increased in STZ-saline and STZ-IMT504 groups; ANOVA, P Ͻ 0.01. *Different from control-saline and control-IMT504, P Ͻ 0.01. G and H: insulin (red), glucagon (blue), and Nkx6.1 (brown). Expression of Nkx6.1, another characteristic marker of adult ␤-cells, was evaluated in islets from all experimental groups G: no. of Nkx6.1ϩ ␤-cells/islet did not vary among groups; ANOVA, NS. H: no. of Nkx6.1ϩ ␣-cells/islet increased in STZ-saline and STZ-IMT504 groups; ANOVA, P Ͻ 0.05. *Different from control-saline and control-IMT504, P Ͻ 0.05. saline vs. control-saline and control-IMT504, P Ͻ 0.01; Cxcl1/Ppib, ANOVA: P Ͻ 0.05, STZ-saline vs. controlsaline, control-IMT504, and STZ-IMT504, P Ͻ 0.04; Fig. 7 , H-J). Pecam1 decreased in both control-IMT504 and STZ-IMT504 islets, demonstrating a clear ODN-dependent effect (ANOVA: P Ͻ 0.01, control-IMT504 and STZ-IMT504 vs. control-saline and STZ-saline, P Ͻ 0.03; Fig. 7K) .
Interestingly, Reg2 significantly increased in STZ-IMT504-treated islets (ANOVA: P Ͻ 0.02, STZ-IMT504 vs. controlsaline and control-IMT504, P Ͻ 0.05; Fig. 7L ).
DISCUSSION
Here we evaluated IMT504 as a possible therapy for immunodependent diabetes. We validated its effectiveness in mice by demonstrating its in vitro MSC cloning capacity and its blood glucose-lowering effect in a model of immunodependent diabetes, which was in line with our previous results in rats (3, 22) .
Regarding the long-term IMT504 effects, this ODN efficiently lowered blood glucose with an 88% response rate. Although in this diabetes model there is some spontaneous reversion (ϳ20% in our colony) (12), the clear difference in the rate demonstrated the specific effect of IMT504. Glucose metabolism showed marked improvement, consistent with islet recovery. Moreover, insulitis was reduced markedly. In this diabetes model, in which the immune attack is incessant, similar to T1D, a partial increase in blood glucose was observed after IMT504 interruption. Because we did not evaluate food intake in these animals, we acknowledge the possibility that reduced food intake may be a factor in the glucose normalization after IMT504 injections, which will have to be determined in future experiments. Although the glycemic control obtained was considerable, drug administration will have to be perfected to attain a more sustained response.
In the short-term analysis, IMT504 reduced blood glucose to control levels, islet parameters had partially recovered, ␤-cell apoptosis was inhibited, and proliferation was induced. Nevertheless, the decrease in insulin-positive area persisted even when islet area increased, suggesting that ␤-cells may not be accumulating enough insulin for its detection by IHC. IMT504 already markedly reduced islet infiltration, demonstrating its immunomodulatory role.
IDO inhibits T cell proliferation, representing an important physiological mechanism controlling both inflammation and autoimmunity (35) . Similar to CpG ODNs (14) , IMT504 increased IDO expression in islets from diabetic mice, suggesting that this may be one mechanism by which it controls islet infiltration, although this should be confirmed by inhibiting IDO action and thus curtailing IMT504 action. Furthermore, IMT504 increased serum IL-6 and TNF independently of whether the mice were diabetic or not, demonstrating an ODN-associated effect. IL-6 is a pleiotropic cytokine with multiple functions (16) proposed to induce protective actions in the short term, whereas in the long term it may play a role in the pathogenesis of disease (16) . Regarding its protective actions, IL-6 modulates the Th1/Th2 balance towards Th2 (11) , favors the presence of M2 immunosuppressor macrophages (33) , and inhibits the proliferation of CD4ϩ and CD8ϩ lymphocytes (15) . Moreover, IL-6 inhibits ␤-cell apoptosis (38) . Therefore, IMT504-induced IL-6 increase may be protecting islets from STZ-induced damage by immunosuppressive and proregenerative actions.
TNF is the prototype of proinflammatory cytokines; nevertheless, its pleiotropic effects often lead to opposing outcomes during the development of immune-mediated diseases (39) . TNF␣ can act as an antiapoptotic signal and promote cell survival and proliferation in certain tissues (40) . The IMT504-induced increase in circulating TNF may help promote ␤-cell survival/proliferation while not stimulating inflammation or apoptosis, as ␤-cell death and islet infiltration were reduced by IMT504. It will be interesting to establish which cells produce IL-6 and TNF in the context of IMT504 stimulation in this diabetes model and the mechanisms by which they may be exerting their beneficial effects. Interestingly, MSCs release IL-6 and IDO, which participate in the anti-inflammatory actions of these cells (15) . Taking into account our previous results (3, 22) and the present preliminary results, we hypothesized that IMT504 could potentially stimulate MSCs to participate in tissue repair and immunomodulation in this diabetes model. In vitro IMT504 increased mouse CFU-F formation, which is an indication of self-renewal stimulation of bone marrow mesenchymal progenitors. However, IMT504 did not stimulate nestin mRNA expression, one postulated marker of pancreas progenitors, in the present conditions (46) . Nevertheless, the potential participation of pancreatic progenitors stimulated by IMT504 in the recovery of ␤-cells cannot be discarded and remains to be explored further in future experiments.
Interestingly, Pdx1 and Nkx6.1 expression increased in ␣-cells in diabetic mice, but not in ␤-cells, independent of IMT504 treatment, suggesting an early event in ␣/␤-transdif- Fig. 7 . Second experimental design. Gene expression (quantitative PCR), which was evaluated in islets isolated from STZ-IMT504 mice after 2 consecutive decreases in blood glucose. Mice from the other experimental groups were euthanized at the same time. A: Ins2/Ppib increased in STZ-saline islets and significantly reverted to control levels in STZ-IMT504 islets; ANOVA, P Ͻ 0.001. *Different from all, P Ͻ 0.04. B: Gcg/Ppib increased in STZ-saline islets and significantly reverted to control levels in STZ-IMT504 islets; ANOVA, P Ͻ 0.001. #Different from all, P Ͻ 0.002. C: Sst/Ppib increased in STZ-saline islets and significantly reverted to control levels in STZ-IMT504 islets; ANOVA, P Ͻ 0.02. *Different from all, P Ͻ 0.03. D: Ins1/Ppib did not vary among the experimental groups; ANOVA, NS. E: Ppy/Ppib did not vary among the experimental groups; ANOVA, NS. F: Pdx1/Ppib tended to decrease in STZ-saline and STZ-IMT504 islets but did not attain statistical significance; ANOVA, NS. G: Mafa/Ppib significantly decreased in STZ-saline and STZ-IMT504 islets with regard to control-saline; ANOVA, P Ͻ 0.04. *Different from STZ-saline and STZ-IMT504, P Ͻ 0.03. H: Nes/Ppib increased in STZ-saline islets and significantly reverted to control levels in STZ-IMT504 islets; ANOVA, P Ͻ 0.01. *Different from all, P Ͻ 0.03. I: Reg1/Ppib increased in STZ-saline islets compared with controls, whereas the expression partially reverted in STZ-IMT504 islets; ANOVA, P Ͻ 0.02. *Different controls, P Ͻ 0.01. J: Cxcl1/Ppib increased in STZ-saline islets and significantly reverted to control levels in STZ-IMT504 islets; ANOVA, P Ͻ 0.05. *Different from all, P Ͻ 0.04. K: Pecam1/Ppib increased in control-IMT504 and STZ-IMT504 islets, suggesting an IMT504-specific effect; ANOVA, P Ͻ 0.01. *Different from control-saline and STZ-saline, P Ͻ 0.03. L: Reg2/Ppib increased in STZ-IMT504 islets, suggesting the participation of this gene in the regeneration of ␤-cells induced by IMT504; ANOVA, P Ͻ 0.02. *Different from controls, P Ͻ 0.05. ferentiation induced by STZ damage, as also demonstrated in other ␤-cell loss models (6, 44, 45) .
Regarding gene regulation, a group of genes was upregulated by islet damage, and their expression was normalized by IMT504 at a time when diabetes control was already evident.
Among them, Ins2 increased its expression probably as a compensatory response to ␤-cell loss. Gcg and Sst have been shown to increase upon ␤-cell damage (45) , in agreement with our results. Nes was induced by islet damage and reversed by IMT504. These results differ from our results in toxic diabetes Nes expression by immunological damage in another mouse diabetes model. We also evaluated members of the regeneration gene family (Reg), as several groups have identified members of this family as being expressed in T1D and during the process of whole islet neogenesis and ␤-cell regeneration in the pancreas (2, 20, 24, 32) . Reg1 showed a similar pattern of expression to Ins2. Reg1 was shown to increase in T1D (32) , and it was also related to ␤-cell death when overexpressed (36) . In agreement with these descriptions, Reg1 was increased in MLDS islets that showed an increased apoptotic index. In the cases of Ins2, Gcg, Sst, Nes, and Reg1, we interpret the decreases in expression after IMT504 treatment as a sign of islet recovery. CXCL1 is expressed by macrophages, neutrophils, and epithelial cells and has neutrophil chemoattractant activity. Interestingly, increased plasma CXCL1 was observed in T1D patients (21) . Moreover, during inflammation, pancreatic macrophages and ␤-cells produce this chemokine, recruiting leucocytes from blood to the islets (10) . The reduced Cxcl1 expression in IMT504-treated diabetic islets may reflect islet recovery or it may imply an IMT504-specific effect, since IL-6 (increased by IMT504) suppresses local CXCL1 expression, contributing to the control of inflammation (34) , suggesting another possible mechanism of action for IMT504.
Other genes encoding for adult ␤-cell-specific transcription factors were downregulated by STZ-induced damage, such as Pdx and Mafa, and this inhibition was not reversed by IMT504, even though diabetes parameters had improved. Although Pdx1 and Mafa have been shown to regulate Ins2 expression, in our experimental conditions no correlation was observed. Since Reg1 showed the same pattern as Ins2, we hypothesize that in these conditions Reg1 may be driving Ins2 expression.
Interestingly, some genes showed an IMT504-specific response. In the case of Pecam1, a significantly decreased expression was observed in both IMT504-treated control and diabetic islets, demonstrating an ODN-specific response. PE-CAM-1 is normally found on endothelial cells, macrophages, T/NK cells, and lymphocytes, among other cells. PECAM-1 plays a functional role mediating leukocyte migration through the perivascular basement membrane (8) . Our results suggest that a decrease in Pecam1 expression could inhibit leukocyte migration into islets, reducing infiltration, a very significant feature of IMT504-treated diabetic mice. Reg2 showed a different pattern from Reg1; it tended to increase due to damage but was significantly upregulated by the combination of damage plus IMT504, indicating that it could be one of the mechanisms by which IMT504 induces ␤-cell regeneration, as evidenced by increased ␤-cell proliferation in the short-term analysis and recuperation of ␤-cell area in the long-term analysis. Similar to our results, other authors have demonstrated that Reg2 plays a dominant role in endogenous ␤-cell regeneration following adjuvant immunotherapy in diabetic mice (24, 25) . Interestingly, all murine Reg genes carry one or more IL-6 response elements in their 5= flanking region (20) . Therefore, increased IL-6, as observed in STZ-IMT504 mice, could stimulate Reg2 expression in islets, promoting ␤-cell restoration. Intriguingly, IL-6 is also expressed by ␤-cells (37), so a local increase in IL-6 could also contribute to the effects observed here.
Future work will analyze whether islet genes up-or downregulated by IMT504 are direct or indirect effects on islet cells, e.g., through circulating cytokines or other factors induced by this ODN. Moreover, translation of these gene products into proteins is necessary for them to exert the postulated effects, which will have to be corroborated.
In all, our results demonstrate that IMT504 induces significant improvement in blood glucose control, ␤-cell recovery, and clear inhibition of islet infiltration in immunodependent diabetic mice, and therefore, it may may be considered as a potential drug for T1D treatment. Furthermore, in preclinical toxicity studies, we demonstrated that IMT504 is a very safe drug (17, 23) . We are presently validating the effects of IMT504 in NOD mice, a spontaneous model of T1D.
In conclusion, we propose that IMT504 meets the three criteria for a useful drug in autoimmune diabetes (18) . 1) It significantly maintains/restores ␤-cells, 2) it markedly inhibits insulitis, and 3) it is easy and cheap to synthesize and safe to administer. Considering these facts, further preclinical and clinical studies to assess the efficacy of the IMT504 in autoimmune diabetes are warranted, in addition to determining its precise mechanism of action.
